Verastem, Inc. (NASDAQ: VSTM) shares rose about 19% on Wednesday, putting the stock at the top of the PRISM Women’s Health Index. The jump followed…
October 14, 2026
October 13, 2026
Oncolytics Expands Pelareorep Patent Portfolio, Targeting Protection Into the Late 2040s
Key Points Oncolytics has secured a new patent in several countries covering pelareorep’s use as a cancer immunotherapy, with a corresponding U.S. patent expected soon….
October 13 is Metastatic Breast Cancer Awareness Day, which spotlights the stage of breast cancer that still has no cure and the emerging companies working…
October 08, 2026
Myriad Genetics Advances Prostate Cancer Biomarker Through SOPHiA GENETICS Collaboration
Key Points Myriad Genetics is partnering with SOPHiA GENETICS to advance its prostate cancer-specific genomic instability score, or PrGIS, in precision oncology work involving AstraZeneca….
Key Points BioLineRx and Hemispherian will present two GLIX1 posters at the Society for Neuro-Oncology annual meeting in Philadelphia. Both presentations are scheduled for November…
September 14, 2026
FDA Approves Telix’s Pixclara for Glioma Brain Cancer Imaging
Key Points The FDA approved Telix Pharmaceuticals’ Pixclara® for PET imaging in patients with glioma, a form of brain cancer. Pixclara is the first FDA-approved…
September 10, 2026
Oncolytics Reports Preclinical Support for Pelareorep Plus Pan-RAS Inhibitor in Colorectal Cancer
Key Points Oncolytics Biotech reported preclinical results evaluating pelareorep with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the study’s initial every-other-day pelareorep…
September 09, 2026
Actuate Reports Preclinical Synergy for Elraglusib With RAS Inhibitors in Pancreatic Cancer
Key Points Actuate Therapeutics reported preclinical data showing that elraglusib enhanced the activity of two investigational RAS-targeted therapies in pancreatic cancer models. The studies tested…
Key Points Adlai Nortye dosed the first patient in Australia in a global Phase 1 trial of AN4035. The U.S. FDA cleared the company’s IND…
September 04, 2026
AbbVie’s Etentamig Shows Strong Results in Phase 3 Blood Cancer Study
Key Points AbbVie’s experimental drug etentamig helped more patients with hard-to-treat multiple myeloma respond to treatment than standard therapies. The drug cut the risk of…
September 01, 2026
bioAffinity Expands CyPath Lung Toward Monitoring Lung Cancer Survivors
Key Points bioAffinity Technologies is advancing CyPath® Lung for use in monitoring lung cancer survivors after treatment. The noninvasive sputum-based test is designed to provide…
August 26, 2026
FDA Approves Revolution Medicines’ Rasonque for Metastatic Pancreatic Cancer, Months Ahead of Schedule
Key Points The FDA approved daraxonrasib under the brand name Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic…